Skip to content

Research at St Andrews

Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial

Research output: Contribution to journalArticle

Author(s)

Augusto Azuara-Blanco, Jennifer Burr, Craig Ramsay, David Cooper, Paul J. Foster, David S. Friedman, Graham Scotland, Mehdi Javanbakht, Claire Cochrane, John Norrie, EAGLE study group

School/Research organisations

Abstract

Background. Primary angle-closure glaucoma is a leading cause of irreversible blindness worldwide. In early-stage disease, intraocular pressure is raised without visual loss. Because the crystalline lens has a major mechanistic role, lens extraction might be a useful initial treatment.
Methods. From Jan 8, 2009, to Dec 28, 2011, we enrolled patients from 30 hospital eye services in five countries. Randomisation was done by a web-based application. Patients were assigned to undergo clear-lens extraction or receive standard care with laser peripheral iridotomy and topical medical treatment. Eligible patients were aged 50 years or older, did not have cataracts, and had newly diagnosed primary angle closure with intraocular pressure 30 mm Hg or greater or primary angle-closure glaucoma. The co-primary endpoints were patient-reported health status, intraocular pressure, and incremental cost-effectiveness ratio per quality-adjusted life-year gained 36 months after treatment. Analysis was by intention to treat. This study is registered, number ISRCTN44464607.
Findings. Of 419 participants enrolled, 155 had primary angle closure and 263 primary angle-closure glaucoma. 208 were assigned to clear-lens extraction and 211 to standard care, of whom 351 (84%) had complete data on health status and 366 (87%) on intraocular pressure. The mean health status score (0·87 [SD 0·12]), assessed with the European Quality of Life-5 Dimensions questionnaire, was 0·052 higher (95% CI 0·015–0·088, p=0·005) and mean intraocular pressure (16·6 [SD 3·5] mm Hg) 1·18 mm Hg lower (95% CI –1·99 to –0·38, p=0·004) after clear-lens extraction than after standard care. The incremental cost-effectiveness ratio was £14 284 for initial lens extraction versus standard care. Irreversible loss of vision occurred in one participant who underwent clear-lens extraction and three who received standard care. No patients had serious adverse events.
Interpretation. Clear-lens extraction showed greater efficacy and was more cost-effective than laser peripheral iridotomy, and should be considered as an option for first-line treatment.
Close

Details

Original languageEnglish
Pages (from-to)1389-1397
Number of pages9
JournalLancet
Volume388
Issue number10052
Early online date29 Sep 2016
DOIs
Publication statusPublished - 1 Oct 2016

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Baseline characteristics of participants in the treatment of advanced glaucoma study: a multicenter randomized controlled trial

    King, A. J., Hudson, J., Fernie, G., Burr, J., Azuara-Blanco, A., Sparrow, J. M., Barton, K., Garway-Heath, D. F., Kernohan, A. & MacLennan, G., 13 Mar 2020, In : American Journal of Ophthalmology. 213, p. 186-194 9 p.

    Research output: Contribution to journalArticle

  2. Femtosecond laser-assisted cataract surgery compared with phacoemulsification cataract surgery (FACT): a randomised non-inferiority trial

    Day, A. C., Burr, J. M., Bennett, K., Bunce, C., Doré, C. J., Rubin, G. S., Nanavaty, M. A., Balaggan, K. S., Wilkins, M. R. & FACT trial group, 3 Mar 2020, In : Ophthalmology. In press, p. 1-8 8 p.

    Research output: Contribution to journalArticle

  3. A randomised, controlled, observer-masked trial of corneal cross-linking for progressive keratoconus in children: the KERALINK protocol

    Chowdhury, K., Dore, C., Burr, J. M., Bunce, C., Raynor, M., Edwards, M. & Larkin, D. F. P., 12 Sep 2019, In : BMJ Open. 9, 9, 6 p., e028761.

    Research output: Contribution to journalArticle

  4. Five-year outcomes of a randomized trial of treatments for varicose veins

    Brittenden, J., Cooper, D., Dimitrova, M., Scotland, G., Cotton, S. C., Elders, A., MacLennan, G., Ramsay, C. R., Norrie, J., Burr, J. M., Campbell, B., Bachoo, P., Chetter, I., Gough, M., Earnshaw, J., Lees, T., Scott, J., Baker, S. A., Tassie, E., Francis, J. & 1 others, Campbell, M. K., 5 Sep 2019, In : New England Journal of Medicine. 381, p. 912-922

    Research output: Contribution to journalArticle

  5. Clear lens extraction for the management of primary angle closure glaucoma: surgical technique and refractive outcomes in the EAGLE cohort

    Day, A. C., Cooper, D., Burr, J., Foster, P. J., Friedman, D. S., Gazzard, G., Che-Hamzah, J., Aung, T., Ramsay, C. R. & Azuara-Blanco, A., Dec 2018, In : British Journal of Ophthalmology. 102, 12, p. 1658-1662 5 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3

    Global Burden of Disease Health Financing Collaborator Network & Cevik, M., 23 Apr 2020, In : Lancet. Online First, 32 p.

    Research output: Contribution to journalArticle

  2. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

    RESTART Collaboration & Sullivan, F., 29 Jun 2019, In : Lancet. 393, 10191, p. 2613-2623 11 p.

    Research output: Contribution to journalArticle

  3. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

    FOCUS Trial Collaboration & Sullivan, F., 19 Jan 2019, In : Lancet. 393, 10168, p. 265-274 10 p.

    Research output: Contribution to journalArticle

  4. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

    Mullen, M., Jin, X. Y., Child, A., Stuart, A. G., Dodd, M., Aragon-Martin, J. A., Gaze, D., Kiotsekoglou, A., Yuan, L., Hu, J., Foley, C., Van Dyck, L., Knight, R., Clayton, T., Swan, L., Thomson, J. D. R., Erdem, G., Crossman, D., Flather, M. & AIMS Investigators, 21 Dec 2019, In : Lancet. 394, 10216, p. 2263-2270

    Research output: Contribution to journalArticle

  5. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

    Thwaites, G. E., Scarborough, M., Szubert, A., Nsutebu, E., Tilley, R., Greig, J., Wyllie, S. A., Wilson, P., Auckland, C., Cairns, J., Ward, D., Lal, P., Guleri, A., Jenkins, N., Sutton, J., Wiselka, M., Armando, G-R., Graham, C., Chadwick, P. R., Barlow, G. & 18 others, Gordon, N. C., Young, B., Meisner, S., McWhinney, P., Price, D. A., Harvey, D., Nayar, D., Jeyaratnam, D., Planche, T., Minton, J., Hudson, F., Hopkins, S., Williams, J., Török, M. E., Llewelyn, M. J., Edgeworth, J. D., Walker, A. S. & United Kingdom Clinical Infection Research Group (UKCIRG), 17 Feb 2018, In : Lancet. 391, 10121, p. 668-678 11 p.

    Research output: Contribution to journalArticle

ID: 246389135

Top